Replication and Genetic Risk Score Analysis for Pancreatic Cancer in a Diverse Multiethnic Population.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
12 2020
Historique:
received: 22 06 2020
revised: 13 08 2020
accepted: 15 09 2020
pubmed: 23 9 2020
medline: 22 12 2021
entrez: 22 9 2020
Statut: ppublish

Résumé

Genome-wide association studies (GWAS) have identified several SNPs associated with pancreatic cancer. No studies yet have attempted to replicate these SNPs in US minority populations. We aimed to replicate the associations of 31 GWAS-identified SNPs with pancreatic cancer and build and test a polygenic risk score (PRS) for pancreatic cancer in an ethnically diverse population. We evaluated 31 risk variants in the Multiethnic Cohort and the Southern Community Cohort Study. We included 691 pancreatic ductal adenocarcinoma (PDAC) cases and 13,778 controls from African-American, Japanese-American, Latino, Native Hawaiian, and white participants. We tested the association between each SNP and PDAC, established a PRS using the 31 SNPs, and tested the association between the score and PDAC risk. Eleven of the 31 SNPs were replicated in the multiethnic sample. The PRS was associated with PDAC risk [OR top vs. middle quintile = 2.25 (95% confidence interval, 1.73-2.92)]. Notably, the PRS was associated with PDAC risk in all ethnic groups except Native Hawaiian (OR per risk allele ranged from 1.33 in Native Hawaiians to 1.91 in African Americans; This is the first study to replicate 11 of the 31 GWAS-identified risk variants for pancreatic cancer in multiethnic populations, including African Americans, Japanese Americans, and Latinos. Our results also suggest a potential utility of PRS with GWAS-identified risk variants for the identification of individuals at increased risk for PDAC across multiple ethnic groups. PRS can potentially be used to stratify pancreatic cancer risk across multiple ethnic groups.

Sections du résumé

BACKGROUND
Genome-wide association studies (GWAS) have identified several SNPs associated with pancreatic cancer. No studies yet have attempted to replicate these SNPs in US minority populations. We aimed to replicate the associations of 31 GWAS-identified SNPs with pancreatic cancer and build and test a polygenic risk score (PRS) for pancreatic cancer in an ethnically diverse population.
METHODS
We evaluated 31 risk variants in the Multiethnic Cohort and the Southern Community Cohort Study. We included 691 pancreatic ductal adenocarcinoma (PDAC) cases and 13,778 controls from African-American, Japanese-American, Latino, Native Hawaiian, and white participants. We tested the association between each SNP and PDAC, established a PRS using the 31 SNPs, and tested the association between the score and PDAC risk.
RESULTS
Eleven of the 31 SNPs were replicated in the multiethnic sample. The PRS was associated with PDAC risk [OR top vs. middle quintile = 2.25 (95% confidence interval, 1.73-2.92)]. Notably, the PRS was associated with PDAC risk in all ethnic groups except Native Hawaiian (OR per risk allele ranged from 1.33 in Native Hawaiians to 1.91 in African Americans;
CONCLUSIONS
This is the first study to replicate 11 of the 31 GWAS-identified risk variants for pancreatic cancer in multiethnic populations, including African Americans, Japanese Americans, and Latinos. Our results also suggest a potential utility of PRS with GWAS-identified risk variants for the identification of individuals at increased risk for PDAC across multiple ethnic groups.
IMPACT
PRS can potentially be used to stratify pancreatic cancer risk across multiple ethnic groups.

Identifiants

pubmed: 32958499
pii: 1055-9965.EPI-20-0963
doi: 10.1158/1055-9965.EPI-20-0963
pmc: PMC7710597
mid: NIHMS1631275
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2686-2692

Subventions

Organisme : NCI NIH HHS
ID : P01 CA236585
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA209798
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA202979
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG007397
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Oncotarget. 2016 Oct 11;7(41):66328-66343
pubmed: 27579533
Arch Intern Med. 2010 May 10;170(9):791-802
pubmed: 20458087
Onco Targets Ther. 2018 May 09;11:2709-2723
pubmed: 29785120
Nat Commun. 2020 Jun 24;11(1):3175
pubmed: 32581250
Nat Genet. 2011 Dec 11;44(1):62-6
pubmed: 22158540
PLoS One. 2018 Sep 7;13(9):e0203386
pubmed: 30192808
Am J Epidemiol. 2000 Feb 15;151(4):346-57
pubmed: 10695593
PLoS One. 2010 Jul 29;5(7):e11824
pubmed: 20686608
Bioinformatics. 2010 Nov 15;26(22):2867-73
pubmed: 20926424
Cancer Med. 2019 Jul;8(7):3592-3603
pubmed: 31066497
Ann Oncol. 2012 Apr;23(4):843-52
pubmed: 21890910
Sci Rep. 2015 Nov 23;5:17018
pubmed: 26592175
Pancreas. 2019 Aug;48(7):931-933
pubmed: 31180980
J Natl Cancer Inst. 2013 Sep 4;105(17):1298-305
pubmed: 23949329
J Natl Med Assoc. 2005 Jul;97(7):972-9
pubmed: 16080667
Nat Genet. 2014 Sep;46(9):994-1000
pubmed: 25086665
PLoS Genet. 2013 Jun;9(6):e1003566
pubmed: 23785302
Nat Commun. 2018 Feb 8;9(1):556
pubmed: 29422604
Nat Genet. 2010 Mar;42(3):224-8
pubmed: 20101243
Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):320-3
pubmed: 23250936
Ann Surg Oncol. 2014 Jul;21(7):2453-62
pubmed: 24609291
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Nutr Cancer. 2013;65(1):157-64
pubmed: 23368926
Pancreatology. 2017 Nov - Dec;17(6):931-935
pubmed: 28988600
Nat Genet. 2015 Aug;47(8):911-6
pubmed: 26098869
Nat Genet. 2009 Sep;41(9):986-90
pubmed: 19648918
Pancreas. 2018 Sep;47(8):958-966
pubmed: 30074526
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Am J Epidemiol. 2009 Aug 15;170(4):403-13
pubmed: 19561064
Ann Oncol. 2014 Oct;25(10):2065-2072
pubmed: 25057164

Auteurs

David Bogumil (D)

Department of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.

David V Conti (DV)

Department of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.
Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.

Xin Sheng (X)

Department of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.

Lucy Xia (L)

Department of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.

Xiao-Ou Shu (XO)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Stephen J Pandol (SJ)

Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Department of Veterans Affairs, Los Angeles, California.

William J Blot (WJ)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Wei Zheng (W)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Loïc Le Marchand (L)

Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.

Christopher A Haiman (CA)

Department of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.
Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.

Veronica Wendy Setiawan (VW)

Department of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California. vsetiawa@usc.edu.
Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH